A global consensus led by Helena J Teede and colleagues has recommended renaming polycystic ovary syndrome as polyendocrine metabolic ovarian syndrome, a change intended to correct the anatomically misleading implication of pathological ovarian cysts. The proposal, published in The Lancet, aims to highlight the endocrine, metabolic, reproductive, dermatological, and psychological features of a condition affecting one in eight women.
The shift from PCOS to PMOS represents more than a terminology update; it seeks to reshape clinical behavior and patient experience by emphasizing the disorder's multisystem burden. Supporters argue the old name under-represented metabolic and broader health impacts, potentially leading to underdiagnosis or mismanagement.
Yet the initiative faces pushback. PCOS Challenge: The National Polycystic Ovary Syndrome Association disputes the exemplar claim, noting that the published record does not yet support it. The organization also points to lower participation from low-income and middle-income countries and Asia—the region with the largest PCOS population—casting doubt on the process's representativeness.
Successful implementation will require addressing distinct geographical phenotypic variations and substantial health-system friction across diverse clinical settings. The authors acknowledge cultural, communication, and implementation considerations were part of their systematic approach.
The debate underscores broader questions about how medical nomenclature evolves and whether renaming alone can drive meaningful changes in diagnosis and care without accompanying education and systemic reforms.